Journal
NATURE REVIEWS ENDOCRINOLOGY
Volume 12, Issue 7, Pages 421-432Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrendo.2016.67
Keywords
-
Categories
Funding
- European Community's Seventh Framework Programme: ObERStress project [281854]
- Ministry of Economy and Competitiveness (MINECO) Instituto de Salud Carlos III [PI12/01814, PIE13/00024]
- Xunta de Galicia [PIE13/00024, 2015-CP079, 2015-CP080]
- FEDER Program of EU [SAF2015-71026-R, BFU2015-70664-R, BFU2014-2502157581-P, BFU2014-55871-P]
- MINECO
- Novo Nordisk Fonden [NNF15OC0016400] Funding Source: researchfish
Ask authors/readers for more resources
AMP-activated protein kinase (AMPK) has a major role in the modulation of energy balance. AMPK is activated in conditions of low energy, increasing energy production and reducing energy consumption. The AMPK pathway is a canonical route regulating energy homeostasis by integrating peripheral signals, such as hormones and metabolites, with neuronal networks. Current evidence has implicated AMPK in the hypothalamus and hindbrain with feeding, brown adipose tissue thermogenesis and browning of white adipose tissue, through modulation of the sympathetic nervous system, as well as glucose homeostasis. Interestingly, several potential antiobesity and/or antidiabetic agents, some of which are currently in clinical use such as metformin and liraglutide, exert some of their actions by acting on AMPK. Furthermore, the orexigenic and weight-gain effects of commonly used antipsychotic drugs are also mediated by hypothalamic AMPK. Overall, this evidence suggests that hypothalamic AMPK signalling is an interesting target for drug development, but is this approach feasible? In this Review we discuss the current understanding of hypothalamic AMPK and its role in the central regulation of energy balance and metabolism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available